Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2968 studies found for:    "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Unknown  Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
22 Completed
Has Results
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.
23 Active, not recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (CHRONOS-1)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
24 Completed
Has Results
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
25 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
26 Completed
Has Results
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
27 Completed
Has Results
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
28 Completed Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody
29 Completed
Has Results
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
30 Completed
Has Results
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
31 Completed Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: GSK461364
32 Terminated Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Tositumomab and iodine I 131 tositumomab;   Procedure: External beam radiotherapy;   Drug: SSKI
33 Active, not recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
34 Completed
Has Results
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen
35 Completed Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab
Condition: Lymphoma, Non-Hodgkin
Intervention:
36 Completed Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab
Condition: Lymphoma, Non-Hodgkin
Intervention:
37 Completed Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Tositumomab 450 mg;   Drug: Tositumomab 35 mg
38 Completed Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Procedure: PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)
39 Completed Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Procedure: high dose chemo then auto hematopoietic cell transplant
40 Completed
Has Results
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Granulocyte colony-stimulating factor plus plerixafor;   Drug: Granulocyte colony-stimulating factor plus placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.